Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
To assess the safety and antiretroviral activity of 2',3'-dideoxyinosine, we enrolled 43 children with symptomatic (Centers for Disease Control class P-2) human immunodeficiency virus infection in a Phase I-II study and monitored them prospectively for the development of ocular complications secondary to HIV infection or drug toxicity. Follow-up ranged from 12 to 103 weeks with a median follow-up of 71 weeks. Three of 43 children (7.0%) developed peripheral atrophy of the retinal pigment epithelium during treatment with 2',3'-dideoxyinosine. The two children with the most severe retinal atrophy were enrolled in the study at the highest dosage studied (540 mg/m2/day). In contrast to findings in children, no retinal atrophy in HIV-infected adults treated with 2',3'-dideoxyinosine has been evident to date.
Whitcup
S M
SM
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892.
Butler
K M
KM
Caruso
R
R
de Smet
M D
MD
Rubin
B
B
Husson
R N
RN
Lopez
J S
JS
Belfort
R
R
Pizzo
P A
PA
Nussenblatt
R B
RB
D001284:Atrophy; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D004585:Electrooculography; D004596:Electroretinography; D005260:Female; D005500:Follow-Up Studies; D005654:Fundus Oculi; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D010857:Pigment Epithelium of Eye / Q000473:pathology; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000209:etiology; D015215:Zidovudine / Q000627:therapeutic use
D015215:Zidovudine; D016049:Didanosine